Sanofi takes a $260M hit to ex­tri­cate it­self from a dis­as­trous al­liance with Lex­i­con

Sanofi spent $300 mil­lion in cash to get in­to a $1.7 bil­lion al­liance with Lex­i­con on their SGLT1/2 di­a­betes drug so­tagliflozin. And now that the drug has been spurned by the FDA af­ter burn­ing through a pro­gram that pro­vid­ed mixed late-stage da­ta and a late shot at a last-place fin­ish, the French phar­ma gi­ant is fork­ing over an­oth­er $260 mil­lion to get out of the deal.

Sanofi’s un­hap­pi­ness was al­ready ap­par­ent when the com­pa­ny — now un­der new CEO Paul Hud­son — post­ed a state­ment back in Ju­ly that they were drop­ping the deal. But it wasn’t that sim­ple. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER